Compound Compare is a feature of Amino Axiom, a free research information and tracking platform that also hosts a compound library, a glossary, vendor directory and articles. The compare view places two compounds next to each other and lines up their structural properties and the research literature attached to each. It lives at Amino Axiom Compound Compare. This walkthrough covers what the view shows, how a researcher working in longevity, redox and cellular aging might read it, and where its limits sit. It describes the feature only; it does not describe use of any compound.
The longevity lane is a good test case because its compounds are chemically very different from one another. A small thiol tripeptide, a dinucleotide coenzyme and a mitochondrial-derived peptide all appear in cellular aging papers, yet they share almost no structural vocabulary. A side-by-side view is useful exactly when two compounds are discussed in the same literature but are not obviously alike.
Which fields does a side-by-side comparison put in view?
A comparison of this kind is organized around a short list of structural identifiers and descriptive fields. For a researcher the most useful are the molecular formula, the molecular weight, the registry number, the chain length or class of the molecule, and the research areas attached to each compound. Reading them in parallel is faster than opening two separate library pages and holding the numbers in memory.
The Ever Vital catalog lists the same identifiers, which makes it easy to cross-check what the compare view displays. Glutathione is listed with the formula C10H17N3O6S, a molecular weight of 307.32 g/mol and CAS 70-18-8. NAD+ is listed with the formula C21H27N7O14P2, a molecular weight of 663.43 g/mol (anhydrous free acid) and CAS 53-84-9. MOTS-c is listed with the formula C100H152N28O22S2, a molecular weight of 2174.59 g/mol and CAS 1627580-64-6. Placed side by side, the three rows already tell a story: a molecule of about 300 Da, one of about 660 Da and one of about 2170 Da, spanning roughly a seven-fold range in mass.
How does a researcher read a comparison of glutathione and NAD+?
These two are the classic redox pair. Both are central to the balance between oxidized and reduced states in the cell, and both appear constantly in oxidative stress and cellular aging models. Structurally, however, they sit in different classes. Glutathione is a gamma-glutamyl tripeptide built from glutamate, cysteine and glycine, and its functional group of interest is the cysteine thiol. NAD+ is a dinucleotide, two nucleotides joined through their phosphate groups, one carrying a nicotinamide ring and the other an adenine base.
The compare view makes that contrast concrete. The mass difference is more than double. The formula for glutathione contains one sulfur and no phosphorus, while the NAD+ formula contains two phosphorus atoms and no sulfur. A researcher designing an assay can use this directly: a method tuned to detect a thiol will not report on a nucleotide cofactor, and mass spectrometry settings for a 307 Da analyte differ from those for a 663 Da analyte.
The research-literature side of the comparison is where the overlap shows. Published work places the two molecules in a shared redox network. The glutathione redox cycle, in which the reduced form and its disulfide are interconverted, depends on a reductase that draws on the reduced form of a related nicotinamide cofactor, NADPH. NAD+ and NADPH are distinct species with distinct roles, and published analyses are careful to separate them, but they sit close together in cellular metabolism. A comparison page that lists both under redox biology makes that adjacency visible in one screen.
What does comparing glutathione with MOTS-c add?
This pairing is less obvious and therefore a better demonstration of why a structured comparison helps. Glutathione is a tripeptide made of three residues. MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome, with the sequence MRWQEMGYIFYPRKLR in the published structural analyses. Both are peptides in the broad sense, and both contain sulfur, but the similarity ends there.
Reading the two together highlights several differences that matter to bench work. Glutathione contains an unusual gamma peptide bond, which is why it resists the peptidases that cleave ordinary alpha peptide bonds; MOTS-c has a conventional backbone and the sequence-dependent properties that come with it, such as charged arginine residues near the C-terminus and aromatic side chains from tryptophan and tyrosine. Glutathione is discussed mainly in terms of its thiol chemistry and redox buffering capacity. MOTS-c is discussed in terms of mitochondrial-derived peptide signaling and its reported links to AMPK pathway activity and one-carbon metabolism in cell models.
The shared thread in the literature is the NADPH supply. Published analyses of one-carbon metabolism describe it as a source of reducing equivalents, and those equivalents feed glutathione regeneration. A researcher reading the two entries together can see where a mitochondrial signaling question and a thiol redox question meet, and can decide whether a single experimental system could address both.
How does a researcher compare NAD+ with MOTS-c?
The third pairing in this set contrasts a cofactor with a signaling peptide. NAD+ is studied as a coenzyme whose cellular availability is tracked alongside sirtuin pathway activity and mitochondrial function in aging models. MOTS-c is studied as a retrograde signal from the mitochondrion to the rest of the cell. Both are linked to mitochondrial health in the literature, but they would be measured in very different ways: NAD+ through metabolite quantification and enzyme activity assays, MOTS-c through immunological or mass spectrometric detection of the peptide and through downstream pathway readouts such as AMPK phosphorylation.
In the compare view this appears as a mismatch in the descriptive fields, which is itself informative. When two compounds share a research area but differ in class, the researcher knows to expect different analytical methods, different storage considerations in the catalog entry, and different controls. The comparison does not rank the compounds against each other. It places the facts next to one another and leaves the interpretation to the reader.
What should a researcher keep in mind about the limits of a comparison?
A side-by-side view is a reading aid, not a source of primary data. Several cautions apply.
First, the identifiers are only as good as their source. Anyone who copies a formula, molecular weight or registry number into a methods section or a spreadsheet should check it against the supplier's batch documentation and against the primary literature. The CAS registry number carries a check digit, which allows a quick arithmetic validation of whether a number is at least well formed, and it is a habit worth keeping.
Second, similar-looking research areas do not imply similar mechanisms. Two compounds can both be indexed under cellular aging while operating through unrelated pathways. The comparison shows where the literature overlaps; it does not show whether the overlap is causal, additive or incidental.
Third, a comparison cannot replace reading the underlying papers. The compare view summarizes what has been published in broad strokes. Experimental details such as the cell line, passage number, medium composition and the concentration range tested are what determine whether a result transfers to a different model, and those details live in the original reports.
Fourth, entries describe research context only. Nothing in a compare view, or in this article, speaks to use outside the laboratory, and none of these compounds is intended for human use.
How can the compare view fit into a literature workflow?
A practical workflow for a longevity researcher might run in four steps. Start from a question, for example whether a given aging model is best probed through thiol redox state or through mitochondrial signaling. Open the compare view with the two candidate compounds and note the structural differences that will constrain the analytical method. Follow the research-area tags into the literature to identify which cell and tissue models have been used for each. Finally, return to the supplier catalog to confirm identifiers, purity documentation and storage specifications for the exact lot being considered.
The compare view works best as the second step. It is quick enough to use early, when the shortlist of compounds is still changing, and it keeps the structural facts visible while the literature reading proceeds. For wider browsing, the rest of the Amino Axiom library is reachable from the Amino Axiom homepage, and the full Ever Vital research catalog is listed under all compounds.
Used this way, the feature does one narrow job well: it reduces the cost of asking whether two compounds are really comparable. In the longevity lane, where the same words (redox, mitochondrial, cellular aging) are applied to molecules of very different sizes and classes, that is a useful question to answer before choosing a model system.
This article is provided for informational and research purposes only. The compounds discussed are research chemicals intended for laboratory use only. They are not drugs, supplements or food, and are not intended to diagnose, treat, cure or prevent any disease. Ever Vital does not sell products intended for human use. Researchers are responsible for compliance with all applicable local, state and federal regulations.
Join the list.
Restock alerts, subscriber discounts, and first access to new compound drops.
